ࡱ> y{x_ @bjbj ~bbj7qXX4hh,:`v"{ { { : : : : : : :$'<>.:%; @{ %%.:XXC:---%XR:-%:--7h"8`/&89Y:0:,8|?'"? 8?8L{ r!-"#*{ { { .:.:*{ { { :%%%%?{ { { { { { { { {  :  TABLE OF CONTENTS Page 4.01 AUTHORITY 1 4.02 DEFINITIONS 1 4.02-1 Authorized Representative 1 4.02-2 Beneficiary 1 4.02-3 Brand Name Drug 1 4.02-4 Covered Drug 1 4.02-5 Generic Drug 1 4.02-6 Mail Order Pharmacy 1 4.02-7 fb88Care Benefits Manual 1 4.02-8 fb88Care Member 1 4.02-9 Medicare Part D 1 4.02-10 Medicare Part D Excluded Drugs 2 4.02-11 Medicare Savings Program 2 4.02-12 National Drug Code (NDC) 2 4.02-13 Non-Preferred Drugs 2 4.02-14 OBRA 90 2 4.02-15 Over-the-Counter Drug (OTC) 2 4.02-16 Participant 2 4.02-17 Pharmacy Provider 2 4.02-18 Preferred Drugs 2 4.02-19 Preferred Drug List 2 4.02-20 Prescription Drug Plan (PDP) 3 4.02-21 Retail Pharmacy 3 4.02-22 Therapeutic Category 3 4.02-23 Usual and Customary Charge 3 4.02-24 Wrap Benefits 3 4.03 ELIGIBILITY 3 4.04 PARTICIPATION IN MEDICARE PART D 4 4.04-1 Authorized Representative 4 4.04-2 Participants Dually Eligible for Medicare Part D 4 4.05 BENEFITS 4 4.05-1 Covered Benefits 4 4.05-2 Prior Authorization 4 4.05-3 Preferred Drug List 5 TABLE OF CONTENTS (cont.) Page 4.06 DISPENSING PRACTICES 5 4.07 FINANCIAL PARTICIPATION (CO-PAYMENT) 5 4.08 ELIGIBILITY LETTER 5 4.09 AMOUNT AND DURATION OF BENEFITS 5 4.10 REIMBURSEMENT 5 4.11 APPEALS 5 4.12 BILLING INSTRUCTIONS. 6 APPENDIX A: COVERAGE CHART 7 4.01 AUTHORITY This benefit is authorized by, and these regulations are issued under, the authority of 22M.R.S.A. 254-D. The Commissioner of the Department of Health and Human Services has delegated the responsibility for administration of the benefit to the Office of fb88Care Services. 4.02 DEFINITIONS 4.02-1 Authorized Representative refers to the Departments authority pursuant to 22 M.R.S.A. 254-D to enroll and reenroll participants into a Medicare Part D plan, apply for Medicare Part D benefits and subsidies on their behalf, and at the Departments discretion, file exceptions and appeals on their behalf. The Department may also identify a designee for this function. 4.02-2 Beneficiary under Medicare Part D means a person who is eligible for benefits and enrolled in a Medicare Part D plan. 4.02-3 Brand Name Drug is defined as a single-source drug, a cross-licensed drug, or an innovator drug. 4.02-4 Covered Drug is a drug for which the Department reimburses under this benefit. See Subsection 4.05 and Appendix A of this Section. 4.02-5 Generic Drugs are drugs other than those defined as brand-name drugs. 4.02-6 Mail Order Pharmacy is a pharmacy provider that dispenses prescription medications by U.S. mail or private carrier. Mail order pharmacies must have a NABP (National Association of Boards of Pharmacy) provider number uniquely identifying the provider as a mail order pharmacy for purposes of billing. Mail order pharmacies must be licensed by the fb88 Board of Pharmacy, enrolled as Medicare and fb88Care providers, and be operating under contract with the Department. Mail order pharmacies must dispense prescription medications from within the United States. Mail order pharmacies must process claims through the States electronic claims processing system to the standards required by the Department. 4.02-7 fb88Care Benefits Manual (MBM) is the fb88Care policy set forth in Department of Health and Human Services, 10-144, Chapter 101, fb88Care Benefits Manual. 4.02-8 fb88Care Member means a person who receives benefits under the fb88Care Program. 4.02-9 Medicare Part D means the prescription drug benefit program provided under the Medicare Prescription Drug Improvement and Modernization Act of 2003, Public Law 108-173. 4.02 DEFINITIONS (cont.) 4.02-10 Medicare Part D Excluded Drugs are those drugs not covered by Medicare Part D pursuant to Title XIX, Section 1927 of the Social Security Act [42 U.S.C. 1396r-8], for which the Department will continue to reimburse if otherwise covered under this Section. The Department will post a complete list of these covered drugs on its designated website, and the list will include but not be limited to the following categories of drugs: over the counter drugs, certain weight loss drugs, agents when used for the symptomatic treatment of cough and cold, vitamins/minerals, outpatient drugs for which associated tests or monitoring must be purchased exclusively from manufacturers, barbiturates, and benzodiazepins. 4.02-11 Medicare Savings Program Eligible refers to a participant who is also eligible for fb88Care through the Medicare Buy-In Program, as defined in the fb88Care Eligibility Manual (MEM) and designated as QMB, SLMB, or QI. 4.02-12 National Drug Code (NDC) is a universal drug coding system for human drugs established by the Federal Food and Drug Administration, as set forth in 21 C.F.R 207. The FDA assigns each drug a unique identification number specifying the labeler/vendor, product, and package. 4.02-13 Non-Preferred Drugs are covered drugs that are not preferred drugs. 4.02-14 OBRA 90 is the Omnibus Budget Reconciliation Act of 1990 as amended. 4.02-15 Over-The-Counter Drug (OTC) is a drug that can be purchased without a prescription. 4.02-16 Participant is an individual who is eligible for and is receiving this benefit. 4.02-17 Pharmacy Provider is a corporation, association, partnership, or individual that either provides pharmacy services pursuant to a provider agreement with fb88Care or is related by ownership or control to an entity that provides fb88Care or DEL Benefit services, and is also a Medicare pharmacy provider. 4.02-18 Preferred Drugs are covered drugs that are clinically efficacious and which have a lower therapeutic category as determined by the Department after reviewing the recommendation of the Drug Utilization Review Committee. 4.02-19 Preferred Drug List (PDL) is a listing of covered drugs setting forth such information as their status as preferred or non-preferred, whether prior authorization may be required, step order, and any other information as determined by the Department to be helpful to participants, pharmacists, prescribers and other interested parties. This benefit utilizes the PDL referenced in Chapter 104, Section 2, Drugs for the Elderly. 4.02 DEFINITIONS (cont.) 4.02-20 Prescription Drug Plan (PDP) is a Medicare Part D plan provider that is also an approved contractor under contract with the DHHS. 4.02.21 Retail Pharmacy is a pharmacy that possesses a valid outpatient pharmacy license issued by the Board of Pharmacy, accepts Medicare assignment, and which serves DEL participants. 4.02-22 Therapeutic Category is a grouping of drugs by comparable therapeutic effect, as determined by the Department. 4.02-23 Usual & Customary Charge is the amount a pharmacy charges to individuals for prescription drugs for which those individuals do not have insurance coverage. 4.02-24 Wrap Benefits are benefits offered through this Section that may include assistance with co-payments, deductibles, premiums and gaps in coverage. Wrap benefits vary for some members, and details of the benefit are outlined in the table in Appendix A. 4.03 ELIGIBILITY An individual is eligible to receive services as set forth in this Section if he or she meets the eligibility requirements established in 10-144 C.M.R. Chapter 333, and adheres to the additional requirements outlined below. Some participants may have restrictions on the type and amount of benefits they are eligible to receive under this Section. The Department will enter enrolled participants into its electronic database. Entry into the Departments electronic database may occur in one of three ways: 1. Auto-enrollment whereby the Department automatically enrolls the participant into an approved PDP and enters the participant into the Departments database; or Self-enrollment by the participant into an approved PDP. Participants who self enroll must communicate their enrollment to the Department, at which time the Department will confirm the information and enter the participant into its database. Providers should inform participants to call the Departments toll free help line at 1-866-796-2463 to report self-enrollment; or  If the Centers for Medicare and Medicaid Services (CMS) enrolls Medicare Savings Program (MSP) participants into an approved PDP. DEL and Part-D eligible fb88Care members can receive wrap benefits through any CMS approved PDP. 4.04 PARTICIPATION IN MEDICARE PART D WRAP BENEFITS Participants must exhaust other pharmacy benefits including Medicare Part D and fb88Care before using benefits under this Section. 4.04-1 Authorized Representative The Department may act as an authorized representative for or appoint a designee to act as an authorized representative for participants who are eligible for Medicare Part D. As an authorized representative, the Department may: deem eligible and enroll and reenroll participants in a Medicare Part D plan; apply for Medicare Part D benefits and subsidies on behalf of enrollees; establish rules by which enrollees may opt out of participation in Medicare Part D; and at its discretion, file exceptions and appeals pertaining to Medicare Part D eligibility or benefits on behalf of enrollees. 4.04-2 Coverage of Drugs Excluded from Coverage under Medicare Part D For participants who are eligible for Medicare Part D, the Department may provide coverage of drugs excluded by Medicare Part D to the same extent that coverage is available to participants who are not eligible for Medicare Part D. 4.05 BENEFITS As detailed in Chapter 104, Section 2, the DEL benefit is limited to drugs of manufacturers that have both a valid rebate agreement with the federal government pursuant to 42 U.S.C. 1396r-8 and a DEL Rebate Agreement. The fb88 Part D Wrap Benefit additionally allows coverage of drugs of manufacturers that may not have both a valid DEL and federal rebate agreement. Drugs may be subject to prior authorization and the step order as set forth in Chapter 104, Section 2. The Department may refuse coverage for a drug when the prescriber cannot demonstrate medical necessity. 4.05-1 Covered Benefits See the chart in Appendix A for a summary of Covered Benefits under this Section. Prior Authorization (PA) The Department may require prior authorization for certain drugs in this benefit, and follows guidelines as set forth in Chapter 104, Section 2. 4.05 BENEFITS (cont.) 4.05-3 Preferred Drug List In order to facilitate appropriate utilization, the Department utilizes the Preferred Drug List as detailed in Chapter 104, Section 2. 4.06 DISPENSING PRACTICES Retail pharmacy providers may dispense up to a 34-day supply of brand name drugs and up to a 90-day supply of generic drugs. Drugs must be dispensed according to guidelines detailed in Chapter 104, Section 2. 4.07 FINANCIAL PARTICIPATION (CO-PAYMENT) The Department requires each participant to pay a co-payment for drugs, as set forth in the chart in Appendix A. There are no exceptions. If the participant refuses to pay the co-payment, the pharmacy will deny the service. 4.08 ELIGIBILITY LETTER The Department of Health and Human Services issues an eligibility card to each eligible participant enrolled in this benefit. A participant must present the eligibility card to the participating pharmacy upon request. 4.09 AMOUNT AND DURATION OF BENEFITS The Department may stop reimbursing for covered drugs if, in any fiscal year, all the funds appropriated for this benefit have been expended. The Department will provide participants and participating pharmacies with prior notice of the date upon which reimbursement will cease. 4.10 REIMBURSEMENT The Department will reimburse participating pharmacies only for drugs that are covered drugs as set forth in fb88Care Benefits Manual, Chapter 101, Chapter II, Section 80, Pharmacy Services, or in fb88 State Services Manual, Chapter 104, Section 2, Drugs for the Elderly Benefit. This benefit is the payor of last resort. If the participant has another prescription drug coverage plan, that plan must be billed first. 4.11 APPEALS Each participant has the right to an administrative hearing to appeal any decision by the Department that adversely affects that participants benefit. These appeal rights are set forth in Chapter 104, Section 1. 4.12 BILLING INSTRUCTIONS Participating pharmacies must bill in accordance with the Departments billing instructions set forth in the pharmacys fb88Care agreement. Appendix A- MAINE PART D WRAP BENEFITS COVERAGE CHART Eligibility GroupCo-Payment Premiums Deductible GapPart D Excluded Drugs*Dual Eligibles Residing in Nursing Facilities N/AN/AN/AN/ACovered as reimbursed under fb88Care Benefits Manual, Chapter II, Section 80 Pharmacy ServicesDual Eligibles residing in Assisted Living and Level I, II, III and IV PNMI Eligibles (as reimbursed under fb88Care Benefits Manual, Chapter III, Appendices C and F, Section 97, Private Non-Medical Institution Services), or who are co-pay exempt under Chapter 1, Section 1.09-2 of the fb88Care Benefits Manual.100% of all co-paymentsN/AN/AN/ACovered as reimbursed under fb88Care Benefits Manual, Chapter II, Section 80 Pharmacy ServicesAll other Dual Eligibles50% of the cost of Brand Name drugs with a cap of $10 per prescription, and 100% of the cost of generics up to $2.50.N/AN/AN/ACovered as reimbursed under fb88Care Benefits Manual, Chapter II, Section 80 Pharmacy ServicesMedicare Savings Program DEL Eligibles (QMB, SLMB, QI) 50% of the cost of Brand Name drugs with a cap of $10 per prescription, and up to $2.50 per generic.N/AN/AN/ACovered as paid under Chapter 104, Section 2, DEL PolicyDEL members eligible for Medicare Part DNot covered100% of Part D Premiums 50% of the Part D deductibleMembers will have copay of 20% plus $2.Covered as paid under Chapter 104 DEL Policy*Please see the following website for a list of covered Part D excluded drugs: HYPERLINK "http://www.mainecarepdl.org"www.mainecarepdl.org (under General Pharmacy Info)      DEPARTMENT OF HEALTH AND HUMAN SERVICES 10-144 Chapter 104 MAINE STATE SERVICES MANUAL SECTION 4 MAINE PART D WRAP BENEFITS ESTABLISHED 1/1/06 LAST UPDATED 11/6/13 PAGE  PAGE 7 DEPARTMENT OF HEALTH AND HUMAN SERVICES 10-144 Chapter 104 MAINE STATE SERVICES MANUAL SECTION 4 MAINE PART D WRAP BENEFITS ESTABLISHED 1/1/06 LAST UPDATED 11/6/13 '-BJgo~  ) 0 D M o x   / 8 I M V e i r   q y = @ Q Z _ ~ C O k t v hMrCJhK1'5CJ\ hXFCJhXFB*CJphhK1'B*CJph hK1'CJ hK1'5CJhK1'M,-ABg~ ) D o $ Tp!`^``a$gdXF$ T!`^``a$gdXF$ !0^`0a$^ $ !a$$h]ha$  / M i  1 2 F G p q T!gdXF T!gdXF0^0gdXF !gdXFgdXF$ T!`^``a$gdXF   = > @ Z _ ` ~  wn0`0gd[$ %dO$ %dO $]a$gdfF$a$$ T!T|^T`|a$gdXF$ T!T|^T`|a$gdXF$ T!0^`0a$gdXF$ T!a$gdXF    ! " A B C b c d e u $a$$ !a$ !"0`0$ !"0`0a$0`0$ !0`0a$$ !^`a$$ !0`0a$u v  0^0 $ $ ^$ ` $  ^$ ` $  p^p`a$ $ L$ ]L^$ ` # }^# `} # ^# `$a$"^ #. QSZkg| Wy=UYlTUa /!>!!!"\"e"򺱺hK1'5CJaJhK1'CJaJ hMrCJ h#)CJ hfFCJhK1'5CJ\ h#)CJ\ hK1'CJ\ hK1'5CJ hK1'CJhK1'hMrFQR_a|}LN3}} $ $  ]^$ ` ~ $ ^$  $ 8^8` 8^8`$a$ $ $ t^$ `tgd[ $ $ t^$ `t $  ^$ ` gd[ $  ^$ ` 34NOKLuju ~ 0^0 $ $ ^$ ` $ ~ 0^0 ~ 0`0 $ `^``$ ~ 0`0a$$ $ `^``a$$ ~ `^``a$ $ $  ^$ `  $ $  ]^$ ` ~ %!&!!!["r $ $ ^$ `gd#) p~ ^` ~ ~ ^~ ` $ $ ^$ `gdMr ~ ~ ^~ ` ~ N ^N ` $ $  ^$ `  $ $  ^$ `  ~ ["\"##$$$$v%w%&&&&0(2(^gd' & F  p0^p`0gd` p7$8$H$ p p07$8$H$^p`0 7$8$H$^^ $ $ ^$ ` $ $ ^$ ` $~ ^~ `a$e"}" ## $$w%x%0(1((((()))")P)))Z,d,,,---////E0^0011$1%11122334455778ŹŹ񤚤 hK1'CJ\hMrhK1'5CJ\hK1'hMrh#)5CJhMrhK1'5CJhPShK1'CJaJhK1'B*CJaJphhPShK1'B*CJaJphhK1'CJaJjhK1'UmHnHu hK1'5CJ hK1'CJhK1'5CJ\32((())))))Q)R)))))****0+1+ & F ^`p^p ^`^^gd1^ & F  p0^p`0gd` 1+{+|+++R,S,,,----////D0E0^0_0^gd6p & Fgd6p ^`@ ^@ p0^p`0"$a$p^p^ & F_0001 1%1&11111J2K222220`0 0^`0  ^` 0`0 0^`0 L]L^@ ^@ gd Z ^`@ ^@ gd6p233334444555577778888  0`0 0^`0gd6p0^0 `^`` ^`0`0^88880919293949j9|999999$If$If$If  !^ 0`0 883949[9i9j9999999Y:Z:;<<<=====>>>? ?0?1?E?F?h?j?k?m?n?p?q?s?t?v???@@@@@@@@輴謨jhMr0J!UhMrCJOJQJ hGCJhMr hMrCJh>jh>UhK1'0JCJjhK1'UhfF hfFCJ\ hfFCJ hK1'CJ\ hK1'5\ hK1'\hK1' hK1'CJ hK1'CJ hK1'5CJ4999999:4444$Ifkd$$Ifl    ֈ !*<9"  $      $  j   t0    944 la99Y:Z:;4+ $IfgdfFkd$$Ifl    ֈ !*<9"$ $ j t0    944 la$If;;;;;<$If<<1<<<82)2 $Ifgdq$Ifkd|$$Ifl    Xֈ !*<9"$ $ j t0    944 la<<<==L=2kd7$$Ifl    ֈ !*<9"$ $ j t0    944 la$IfL======$If== >,>E>b>71111$Ifkd$$Ifl    ֈ !*<9"$ $ j t0    944 laytfFb>>>>g?(kd$$Ifl    ֈ !*<9"$ $ j t0    944 laytfF$If $IfgdMrg?h?i?j?l?m?o?p?r?s?u?v???? $ !f!a$ !fkd$$Ifl    <99  t0    944 la$If?@@@$@%@&@1@2@3@4@5@]@p@@ $ !f!a$$a$ $&`#$a$&`#$ $ !H$$d&dNPa$gdXF $ !H6$$d&dNPa$gdXF@"@#@$@&@'@-@.@/@0@1@3@4@5@@@@@@@@@@@@@@쿹쫞hK1'h6BhMraJh>hMrCJOJQJ hGCJ hMrCJ hMrCJheWe0J!CJmHnHuhMr0J!CJjhMr0J!CJUhMrjhMr0J!U hMr0J!@@@@@@@@@@@ !gd6B $ !H$$d&dNPa$gdXF $ ! 8$d&dNPa$gdXF 800P/ =!"#$% Dp90P&P/ =!"#$% Dp?P1h0:p5= /!"@#J$@% Dp$$If!vh#v"#v$ #v#v#v$ #vj:V l t0    95"5$ 555$ 5j/  $$If!vh#v"#v$ #v#v#v$ #vj:V l t0    95"5$ 555$ 5j$$If!vh#v"#v$ #v#v#v$ #vj:V lX t0    95"5$ 555$ 5j$$If!vh#v"#v$ #v#v#v$ #vj:V l t0    95"5$ 555$ 5j$$If!vh#v"#v$ #v#v#v$ #vj:V l t0    95"5$ 555$ 5j/ ytfF$$If!vh#v"#v$ #v#v#v$ #vj:V l t0    95"5$ 555$ 5j/ / / ytfF}$$If!vh#v9:V l t0    959/  ^) 666666666vvvvvvvvv666666>6666666666666666666666666666666666666666666666666hH6666666666666666666666666666666666666666666666666666666666666666662 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~_HmH nH sH tH <`< 5NormalCJ_HmH sH tH h@h 5 Heading 17$$ !%d@&O^`a$CJH@H 5 Heading 2$ & F@& CJOJQJ>@> 5 Heading 3$@& 5CJ\`@` 5 Heading 4/$$ !0%d@&O`0a$CJZ@Z 5 Heading 5)$`%d@&O^``CJ<@< 5 Heading 6$@&5CJB@B 5 Heading 7$$@&a$5CJDA D Default Paragraph FontRi@R 0 Table Normal4 l4a (k ( 0No List VoV |7Heading 1 Char"5CJ KH OJPJQJ\^JaJ @o@ |7Heading 2 Char CJOJQJRoR |7Heading 3 Char5CJOJPJQJ\^JaJRo!R |7Heading 4 Char5CJOJPJQJ\^JaJXo1X |7Heading 5 Char$56CJOJPJQJ\]^JaJRoAR |7Heading 6 Char5CJOJPJQJ\^JaJLoQL |7Heading 7 CharCJOJPJQJ^JaJ4@b4 50Header  !2oq2 |70 Header CharCJ4 @4 50Footer  !2o2 |70 Footer CharCJRT@R 50 Block Text$hh]h^ha$ CJOJQJVC@V 50Body Text Indent$h^ha$ CJOJQJFoF |70Body Text Indent CharCJ:U`: 50 Hyperlink>*B*^JphF0@F 50 List BulletCJOJQJ^JaJ6>@6  5Title$a$ 5CJ\NoN |7 Title Char"5CJ KHOJPJQJ\^JaJ 2)`2 50 Page Number^JLR@"L #50Body Text Indent 2 "^CJJo1J "|70Body Text Indent 2 CharCJTS@BT %50Body Text Indent 3$0^`0CJNoQN $|70Body Text Indent 3 CharCJaJJV`aJ 50FollowedHyperlink>*B* ^JphH@rH (50 Balloon Text'CJOJQJ^JaJBoB '|70Balloon Text CharCJaJPK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭V$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3N)cbJ uV4(Tn 7_?m-ٛ{UBwznʜ"Z xJZp; {/<P;,)''KQk5qpN8KGbe Sd̛\17 pa>SR! 3K4'+rzQ TTIIvt]Kc⫲K#v5+|D~O@%\w_nN[L9KqgVhn R!y+Un;*&/HrT >>\ t=.Tġ S; Z~!P9giCڧ!# B,;X=ۻ,I2UWV9$lk=Aj;{AP79|s*Y;̠[MCۿhf]o{oY=1kyVV5E8Vk+֜\80X4D)!!?*|fv u"xA@T_q64)kڬuV7 t '%;i9s9x,ڎ-45xd8?ǘd/Y|t &LILJ`& -Gt/PK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!0C)theme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] 8d318~:~u~ ppppps e"8@@!',2=  u 3["2(1+_02899;<<L==b>??@@"#$%&()*+-./013456789:;<>707E78Xs!!8@Z(  \  # #" ? \  # #" ? B S  ?w0 85d!4t5!tm.n.o.p.q.r.s.t.u.v.w.x.y.z.{.|.}.~.........> >  &&=1=1=1@1%5%5%5-57777p8p8p8v88     B B    &&?1E1E1E1,50505057777u8{8{8{88  =*urn:schemas-microsoft-com:office:smarttags PlaceType=*urn:schemas-microsoft-com:office:smarttags PlaceNameB*urn:schemas-microsoft-com:office:smarttagscountry-region9*urn:schemas-microsoft-com:office:smarttagsplace9*urn:schemas-microsoft-com:office:smarttagsState8*urn:schemas-microsoft-com:office:smarttagsCity H6| _2h222'404j7l7m7o7p7r7s7u7v78888@Y[ 6 ? OxU`fk##j7l7m7o7p7r7s7u7v788883333333333333333IJno00LMwx 78UVqr ppxyZZOO  TUQ!Q!$$J*J*j1j1Z2Z2224456 6+6b6b6v6w6667F7i7i7j7j7m7m777778888888#8&8085888IJno00LMwx 78UVqr xyZZOOQ!Q!J*J*j1j1Z2Z2224456 6+6b6b6v6w6667F7i7i7j7j7l7m7m7o7p7r7s7u7v77777888888588888=}0cVR=Rglt."HBxC m hh^h`OJQJo(  ^ `^Jo(.  ^ `^J.xLx^x`L^J.HH^H`^J.^`^J.L^`L^J.^`^J.^`^J.X LX ^X `L^J.`^``^Jo(p`p^p``^Jo(.@ `@ ^@ ``^Jo(.-`^``^Jo(.-. `^``^Jo( .-.. `^``^Jo( .-... `^``^Jo( .-.... P`P^P``^Jo(.-..... ^`^Jo(.-......  ^ `^Jo(.  ^ `^J.xLx^x`L^J.HH^H`^J.^`^J.L^`L^J.^`^J.^`^J.X LX ^X `L^J.p0p^p`0^Jo(.  ^ `^J. L ^ `L^J.xx^x`^J.HH^H`^J.L^`L^J.^`^J.^`^J.L^`L^J.C m0cV."HgL.        b        ð~˚G V|̢tZKMNd h"*<` / !o-F"UU&0'K1'K*i.565v>FDXFfFDLSPSA;UpY Z]^p^?)`pc eeWe*6gOov$rMrJt:u5[d6p{d ''s#5qZ$#)A~<86B3M~ M$J)1GETn1jnW>|9j7l7@ 8@UnknownG* Times New Roman5Symbol3. * Arial7@Cambria7.@ Calibri5. *aTahomaA$BCambria Math"Ah+E%/ dE%/ d#24N7N73HX ?:u2!xx %F:\JEAND\WINWORD\TEMPLATE\KINGLET.DOT5/24/95prior authorizationprior authorizationBrenda Trussel Don Wismer      Oh+'0 h|     5/24/95prior authorizationBrenda Trusselprior authorization`ltr to case head to inform of need for primary care physician to provide prior authorization KINGLET.DOT Don Wismer5Microsoft Office Word@0@芤@C@6] E%/՜.+,D՜.+,H hp  Dept. of Human ServicesdN7 5/24/95 Title 8@ _PID_HLINKSAtZYhttp://www.mainecarepdl.org/  !"#$%&'()*+,-./0123456789:;<=>?ABCDEFGIJKLMNOPQRSTUVWXYZ[\]^_`abcdefgijklmnoqrstuvwzRoot Entry FP |Data @1TableH?WordDocument~SummaryInformation(hDocumentSummaryInformation8pCompObjr  F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q